AbbVie Announces Positive Topline Results from Phase 3 AFFIRM Study Evaluating SKYRIZI® Subcutaneous Induction in Patients with Crohn's Disease

NodeGuardian · 2026-03-13T13:05:20+00:00

AbbVie's Phase 3 AFFIRM study showed that risankizumab (SKYRIZI®) effectively induces clinical remission and endoscopic response in adults with active Crohn's disease, meeting its primary endpoints with a consistent safety profile.

NodeGuardian

2026-03-13 13:05:20

Abstract generation in progress

AbbVie announced positive topline results for its Phase 3 AFFIRM study of risankizumab (SKYRIZI®) subcutaneous induction treatment for adults with moderately to severely active Crohn’s disease. The study met its co-primary endpoints, demonstrating superior clinical remission and endoscopic response at week 12 compared to placebo. The safety profile was consistent with previous findings, and the results reinforce SKYRIZI’s efficacy, especially in a difficult-to-treat patient population.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.